Ovarian function suppression (OFS) is considered an important aspect of treatment in premenopausal
women with advanced
endocrine-responsive
breast cancer. Degarelix is a gonadotropin-releasing hormone (GnRH) antagonist, which, when bound to GnRH receptors in the pituitary, results in a decreased secretion of gonadotropins. In men, this leads to a rapid decrease in the production of testosterone, […]